David Cobb, Head UK Partner and John Moore, Director, of Deloitte & Touche's Research and Development Tax Services team remind us of the basics of Vaccine Research relief
David Cobb Head UK Partner and John Moore Director of Deloitte & Touche's Research and Development Tax Services team remind us of the basics of Vaccine Research relief
The start date for expenditure qualifying for the generous Vaccine Research Relief has finally been announced in a recent Statutory Instrument after a wait of a year. It may be recalled that the Finance Act 2002 contained legislation aimed at boosting UK R&D spending on certain types of vaccines and medicines. Whilst this was all well and good the start date had to be delayed while the Government obtained confirmation from the European Commission that...
If you or your firm subscribes to Taxjournal.com, please click the login box below:
If you do not subscribe but are a registered user, please enter your details in the following boxes:
David Cobb, Head UK Partner and John Moore, Director, of Deloitte & Touche's Research and Development Tax Services team remind us of the basics of Vaccine Research relief
David Cobb Head UK Partner and John Moore Director of Deloitte & Touche's Research and Development Tax Services team remind us of the basics of Vaccine Research relief
The start date for expenditure qualifying for the generous Vaccine Research Relief has finally been announced in a recent Statutory Instrument after a wait of a year. It may be recalled that the Finance Act 2002 contained legislation aimed at boosting UK R&D spending on certain types of vaccines and medicines. Whilst this was all well and good the start date had to be delayed while the Government obtained confirmation from the European Commission that...
If you or your firm subscribes to Taxjournal.com, please click the login box below:
If you do not subscribe but are a registered user, please enter your details in the following boxes:
